07:00 , May 29, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Bradykinin receptor Rat and in vitro studies identified dynorphin A analogs that antagonize bradykinin receptors and...
08:00 , Nov 1, 2004 |  BioCentury  |  Product Development

Treating HAE

Treating HAE In normal patients, C1 esterase inhibitor can normalize inflammation by intervening to slow formation of prekallikrien from Factor XIIa or by inhibiting conversion of HMW-kininogen. Kallikrein mediates the release of bradykinin from precursors. But...
08:00 , Nov 1, 2004 |  BioCentury  |  Product Development

The Dyax-Jerini showdown

Locked in a race to market with Jerini AG with rival compounds to treat hereditary angioedema (HAE), Dyax Corp. had been aiming to submit a BLA for its DX-88 recombinant kallikrein inhibitor protein next year....